Ebola Virus Net is the web resource for anyone interested in ebola. Ebola (Ebola hemorrhagic fever), is a severe, often fatal disease in humans and nonhuman primates such as monkeys, gorillas, and chimpanzees. Ebola is a rare and deadly disease caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There are five identified Ebolavirus species, four of which have caused disease in humans. Ebola is found in several African countries. The first Ebola species was discovered in 1976 near the Ebola River in the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The largest outbreak to date was the epidemic in West Africa, which occurred from December 2013, to January 2016, with 28,646 cases and 11,323 deaths. Other outbreaks in Africa began in the Democratic Republic of the Congo in May 2017 and 2018. In July 2019, the World Health Organization declared the Congo Ebola outbreak a world health emergency.

When an infection does occur in humans, the virus can be spread to others through direct contact with the blood or body fluids of a person who is sick with Ebola, or through contact with objects that have been contaminated with the blood or body fluids of an infected person. Until recent, no vaccines were effective. In December 2016, Ebola was found to be 70–100% prevented by rVSV-ZEBOV vaccine, making it the first proven vaccine against the disease. More than 100,000 people have been vaccinated against Ebola as of 2019.

The objectives of Ebola Virus Net are to be the public and professional information resource for ebola and to serve as a network in the exchange of information and news related to ebola.

• Experimental NIH Sudan virus vaccine protects macaques - National Institutes of Health (.gov)
  Fri, 03 Feb 2023 15:16 GMT
• Uncovering the first FDA-approved drug for Ebola virus infection - Drug Target Review
  Mon, 06 Feb 2023 12:38 GMT
• Uganda’s Worst Ebola Outbreak in Two Decades Is Over, W.H.O. Declares - The New York Times
  Wed, 11 Jan 2023 08:00 GMT
• ‘A great day for the country’: Uganda declares an end to Ebola outbreak - The Guardian
  Wed, 11 Jan 2023 08:00 GMT
• Randomized Trial of Vaccines for Zaire Ebola Virus Disease | NEJM - nejm.org
  Thu, 29 Dec 2022 08:00 GMT
• Flu, MERS and Ebola — the disease outbreaks most frequently reported - Nature.com
  Fri, 27 Jan 2023 08:00 GMT
• News at a glance: Ebola vaccine trial on hold, Oppenheimer's name cleared, and the return of a long-forgotten coffee ... - Science
  Thu, 22 Dec 2022 08:00 GMT
• Uganda declares end of Ebola disease outbreak | WHO | Regional Office for Africa - WHO | Regional Office for Africa
  Wed, 11 Jan 2023 08:00 GMT
• Epidemics That Weren't: How Countries Shut Down Recent Outbreaks - The New York Times
  Tue, 03 Jan 2023 08:00 GMT
• Penn scientists discover a cellular pathway that keeps Ebola virus from exiting human cells - News-Medical.Net
  Fri, 03 Feb 2023 23:08 GMT
• Ebola disease caused by Sudan ebolavirus – Uganda - World Health Organization
  Sat, 14 Jan 2023 08:00 GMT
• Structure and function of the first FDA-approved treatment for Ebola virus discovered - News-Medical.Net
  Tue, 31 Jan 2023 00:31 GMT
• Uganda declares end of Ebola virus outbreak - UN News
  Wed, 11 Jan 2023 08:00 GMT
• Uganda Ebola outbreak highlights need for vaccine stockpile - STAT
  Wed, 11 Jan 2023 08:00 GMT
• Ebola Vaccine Booster Found Very Effective - Precision Vaccinations
  Thu, 02 Feb 2023 16:06 GMT

• PRO/AH/EDR> Ebola update (44): Burkina Faso ex Cote d'Ivoire, 2nd case, NOT
  Mon, 30 Aug 2021 11:01:25 -0400
  Ebola -- Burkina Faso
  On 22 Aug 2021, the Ministry of Health informed the population of the admission to the Medical Emergencies of the Bogodogo University Hospital (CHU-B) of a 22-year-old patient who had stayed in the Republic of [Cote d'Ivoire]. The diagnostic procedure consisted of sampling analysis at the National Reference Laboratory for Viral Haemorrhagic Fever (LNR-FHV at the Muraz Centre) and the Pasteur Institute of Dakar for confirmation. The results obtained make it possible to permanently rule out

• Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques Sun, 05 Feb 2023 06:00:00 -0500
  BACKGROUND: The recent Sudan virus (SUDV) outbreak in Uganda highlights the need for rapid response capabilities, including development of vaccines against emerging viruses with high public health impact. We aimed to develop a Sudan virus-specific vaccine suitable for emergency use during outbreaks.
• Solidarity Against Ebola: an update Sun, 05 Feb 2023 06:00:00 -0500
  No abstract
• Hendra Virus: An Update on Diagnosis, Vaccination, and Biosecurity Protocols for Horses Fri, 03 Feb 2023 06:00:00 -0500
  Hendra virus (HeV) emerged as a zoonotic pathogen in the 1990s, causing low morbidity but high mortality in humans and horses. Pteropid bats are the natural reservoir of HeV and other important zoonotic viruses such as Nipah and Ebola viruses. Equivac HeV, manufactured by Zoetis (Parkville, Victoria, Australia), is the only commercially available vaccine for horses. There is no commercial vaccine for humans. The epidemiology, clinical features, pathology, diagnosis, management, and prevention of...
• Characterization of an air-liquid interface primary human vaginal epithelium to study Ebola virus infection and testing of antivirals Thu, 02 Feb 2023 06:00:00 -0500
  Ebola virus (EBOV) is the causative agent of the often-fatal Ebola virus disease (EVD) characterized by hemorrhagic fever in humans and non-human primates. Sexual transmission from male survivors has been at the origin of multiple outbreak flare-ups between 2015 and 2021. However, this route is still poorly understood and the resulting EVD from it is also understudied. To support epidemiological studies documenting sexual transmission to women, and as a transition from previously using monolayer...
• Infectious diseases, dividend policy, and independent directors: Evidence from textual analysis Thu, 02 Feb 2023 06:00:00 -0500
  We investigated the effect of uncertainty associated with infectious diseases on corporate dividend policy. We used a unique text-based measure of infectious diseases that includes not only the Covid-19, but also other important diseases, such as SARs, MERs, and Ebola. Based on a sample of 287,151 firm-year observations across four decades (from 1985 to 2021), our results show that a higher level of uncertainty associated with infectious diseases significantly reduce dividends. Interestingly, we...
• Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP) Wed, 01 Feb 2023 06:00:00 -0500
  While effective at preventing Zaire ebolavirus (ZEBOV) disease, cellular immunity to ZEBOV and vector-directed immunity elicited by the recombinant vesicular stomatitis virus expressing ZEBOV glycoprotein (rVSVΔG-ZEBOV-GP) vaccine remain poorly understood. Sera and peripheral blood mononuclear cells were collected from 32 participants enrolled in a prospective multicenter study [ClinicalTrials.gov NCT02788227] before vaccination and up to six months post-vaccination. IgM and IgG antibodies,...
• Application and comparison of lyophilisation protocols to enhance stable long-term storage of filovirus pseudotypes for use in antibody neutralisation tests Wed, 01 Feb 2023 06:00:00 -0500
  CONCLUSIONS: Filovirus PVs are amenable to lyophilisation and can be stored for at least 2 years in a household fridge to be used in antibody assays. Lyophilisation performed in the right conditions would allow transportation at room temperature, even in warmer climates.
• Marburg virus disease: the paradox of Nigeria's preparedness and priority effects in co-epidemics Wed, 01 Feb 2023 06:00:00 -0500
  BACKGROUND: The recent outbreaks of Marburg virus disease (MVD) in Guinea and Ghana have become a major public health concern not only to the West African sub-region but a threat to global health.
• Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections Tue, 31 Jan 2023 06:00:00 -0500
  Novel effective drugs or therapeutic vaccines have been already developed to eradicate viral infections. Some non-viral carriers have been used for effective drug delivery to a target cell or tissue. Among them, cell penetrating peptides (CPPs) attracted a special interest to enhance drug delivery into the cells with low toxicity. They were also applied to transfer peptide/protein-based and nucleic acids-based therapeutic vaccines against viral infections. CPPs-conjugated drugs or vaccines were...
• The Role of Ultrasound in Pediatric Skull Fractures: Determination of Fracture and Optic Nerve Sheath Diameter Measurements Tue, 31 Jan 2023 06:00:00 -0500
  CONCLUSIONS: When used with clinical decision rules to minimize the risk for clinically important traumatic brain injury, POCUS seems to be a promising tool to detect skull fractures and calculate ONSD measurements and rates to predict the risk for SOLs and perform further risk stratification of children with minor head trauma.